MHRA Gov UK- SCOPE ADR campaign on reporting side effects - EURORDIS

About us

About EURORDIS

Our History

Our Team

Our Initiatives & Programmes

Projects and Partnerships

Our governance

Our Governance charts and External Representation

Our Board of Directors

Our Strategy & Impact

Our Funding

Annual Reports, Statutes and By-Laws

Our network

Members

National Alliances

European Federations

Volunteers

Advocacy

Rare disease policy

Rare Cancers

European Action Plan for Rare Diseases

Parliamentary Advocates for Rare Diseases

Priority areas

Diagnosis

Research

Holistic care

Treatments

Cross-cutting areas

European Reference Networks

EURORDIS Ukraine Response

About rare diseases

What is a rare disease?

Information on your rare disease

Rare diseases in the arts

Personal stories

About treatments for rare diseases

FAQ: rare disease treatments

List of the marketing authorisations

Compassionate use

Pharmacovigilance

Find support

Connect with a patient organisation

Rare disease helplines

Find a specialised Social Service

Find medical expertise

Find a community

With EURORDIS

Become a member

Join the EURORDIS Round Table of Companies

ERTC Resources

Support EURORDIS

Careers

With our programmes & initiatives

EURORDIS Open Academy

Rare Barometer

Rare Disease Day

RareConnect

EURORDIS Community Advisory Board Programme

With our events

Black Pearl Awards

European Conference on Rare Diseases (ECRD)

Membership Meeting

Rare Disease Week

November 2016

MHRA Gov UK- SCOPE ADR campaign on reporting side effects

Home » MHRA Gov UK- SCOPE ADR campaign on reporting side effects